Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B

导出原文传递

翻译打印收藏纠错

作者： Gane, Edward J. ^[1] ; Kim, Hyung Joon ^[2] ; Visvanathan, Kumar ^[3] ; Kim, Yoon Jun ^[4] ; Anh-Hoa Nguyen ^[5] ; Wallin, Jeffrey J. ^[6] ; Chen, Diana Y. ^[7] ; McDonald, Circe ; Arora, Priyanka ; Tan, Susanna K. ; Gaggar, Anuj ; Roberts, Stuart K. ; Lim, Young-Suk

作者单位： Seoul Natl Univ Hosp, Seoul, South Korea ^[1] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA ^[2] Alfred Hosp, Melbourne, Vic, Australia ^[3] Chung Ang Univ Hosp, Seoul, South Korea ^[4] Auckland City Hosp, New Zealand Liver Transplant Unit, Private Bage 1142, Auckland, New Zealand ^[5] St Vincents Hosp Melbourne, Fitzroy, Vic, Australia ^[6] Univ Ulsan, Asan Med Ctr, Coll Med, Seoul, South Korea ^[7]

发布时间 2021-12-10

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Hepatology

2021年74卷4期

1737-1749页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B

Hepatology

相似文献

Hepatology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B

Hepatology

相似文献

Hepatology

相关期刊

检索历史清除